Drug companies that manufacture ketamine are expected to lead profits in the category, according to an Anesthesia Drug Market study. Ketalar, distributed by JHP Pharmaceuticals, is currently the only branded version of the drug offered on the market.
Ketalar is expected to maintain a high profile in the market over the next five years, according to the study, but could see a drop in sales due to an increasing demand for less expensive generic counterparts.
Related Articles on Anesthesiology:
Two Anesthesiologists Selected to Lead St. Joseph Medical Center Anesthesia Department
Anesthesiologist Receives American Pain Society Award
Anesthesiologist Elected to Massachusetts Medical Society House of Delegates
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
